Novo Nordisk Files Routine 6-K Report
Ticker: NONOF · Form: 6-K · Filed: Aug 6, 2025 · CIK: 353278
Sentiment: neutral
Topics: sec-filing, 6-k, routine-disclosure
TL;DR
Novo Nordisk filed a 6-K, standard report, no new info.
AI Summary
Novo Nordisk A/S filed a Form 6-K on August 6, 2025, reporting its financial information as of June 30, 2025. The filing is a routine report for foreign private issuers and does not contain specific financial results or material events beyond its status as a periodic disclosure.
Why It Matters
This filing serves as a standard disclosure for foreign private issuers, providing the SEC with updated information about the company's status and administrative details.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material financial or operational information that would typically impact stock price.
Key Players & Entities
- NOVO NORDISK A S (company) — Filer
- 0001628280-25-038087 (filing_id) — Accession Number
- 20250806 (date) — Filing Date
- 20250630 (date) — Period of Report
- DK-2880 Bagsværd Denmark (location) — Principal Executive Offices
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to report information that the company has made or is required to make public in its home country.
What is the filing date of this report?
The filing date of this report is August 6, 2025.
What period does this report cover?
The conformed period of report for this filing is June 30, 2025.
Is Novo Nordisk A/S required to file annual reports under Form 20-F?
Yes, the registrant indicates by check mark that it files annual reports under cover of Form 20-F.
What is the principal executive office address for Novo Nordisk A/S?
The address of the principal executive offices is Novo Allé DK-2880 Bagsværd Denmark.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 6, 2025 regarding NOVO NORDISK A S (NONOF).